icon-folder.gif   Conference Reports for NATAP  
 
  EASL 46th Annual Meeting
March 30th - April 3rd 2011
Berlin, Germany
Back grey_arrow_rt.gif
 
 
 
Effects of Tenofovir DF on Renal Function of Chronic HBV Patients in Three Global Randomized Studies
 
 
  Reported by Jules Levin EASL 2011 Berlin German March 30-Apr 2
 
P. Marcellin1, J. Heathcote2, T. Berg3, J. Anderson4, E. Mondou4, D. Coombs4, R. Ebrahimi4, S. Reddy4, U. Lopatin4, C. Ng4 1Hospital Beaujon, Clichy, France; 2Toronto Western Hospital, University of Toronto, Ontario, Canada; 3Universitatsklinik, Leipzig, Leipzig, Germany; 4Gilead Sciences Inc., Foster City, CA, USA.
 
Author Discussion
· This analysis evaluated the renal function of 675 patients on TDF for up to 3 years
· Overall, few patients experienced a decline in renal function - 5/675 (0.7%) had ≥ 0.5mg/mL increase in creatinine
· 3/5 had preexisiting hypertension
· 1/5 had preexisting diabetes
- 1/675 (0.1%) had a decline in eGFR to <50ml/min
· This patient had preexisting hypertension
· The lack of a placebo group in these long term studies makes conclusions concerning the potential role of TDF in decreasing renal function more difficult to assess. Patients with diabetes and hypertension are already at risk for renal dysfunction regardless of TDF therapy

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif